Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERANDA-IIM phase 3 trial of nerandomilast added to background therapy in active idiopathic inflammatory myopathy
jRCT2071260103Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Autoimmune Myopathies comparing Nerandomilast + background therapy with Placebo + background therapy (2 arms). Primary endpoint: Total improvement score at Week 52. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
nerandomilast
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on jRCT2071260103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260103.